Abstract
An identification of PAC1- and VPAC-type receptors in a great number of neoplastic cells gave rise to intensive studies on the biochemical and physiological role of the mentioned peptides in cancers. Our earlier studies focused on effects of pituitary adenylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP) in C6 glioma cells have shown their stimulatory receptor-mediated action on the cyclic adenosine monophosphate (cAMP)-generating system. In the present study, we demonstrated that truncated peptides, i.e., PACAP6-38 and VIP6-28, both produced a significant inhibition of the VIP-induced increase in cAMP production, whereas only PACAP6-38 did antagonize the PACAP-38 effect. In contrast to the well-expressed PACAP-38 and VIP effects on cAMP production in C6 cells, helodermin and secretin were poorly active as cAMP stimulators in this cell line, displaying some activity only at a high 5-μM dose. PACAP-38 and, to a lesser extent VIP stimulated the proliferation of C6 glioma cells, which was shown by an increased incorporation of 3H-thymidine into the cells, and the effects of these two peptides were antagonized by PACAP6-38. The truncated PACAP (10 μM) by itself significantly inhibited C6 cell proliferation. The study with the use of forskolin and dibutyryl-cAMP revealed that the growth effects of PACAP were cAMP independent. Our findings suggest that glioma C6 cells possess PAC1- and VPAC-type receptors, but the density of PAC1 seems to be much larger than VPAC receptors. Although the proliferative activity of PACAP and VIP is mediated via the PAC1-type receptor, the signaling cascade underlying this phenomenon does not seem to involve cAMP.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arimura, A. (1998). Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Japanese Journal of Physiology, 48, 301–331.
Bik, W., Wolinska-Witort, E., Pawlak, J., Skwarlo-Sonta, K., et al. (2006). PACAP38 as a modulator of immune and endocrine responses during LPS-induced acute inflammation in rats. Journal of Neuroimmunology, 177, 76–84.
Dalsgaard, T., Hannibal, J., Fahrenkrug, J., Larsen, C. R., et al. (2003). VIP and PACAP display different vasodilatory effects in rabbit coronary and cerebral arteries. Regulatory Peptides, 110, 179–188.
Dejda, A., Jozwiak-Bebenista, M., & Nowak, J. Z. (2006). PACAP, VIP, and PHI: Effects on AC-, PLC-, and PLD-driven signaling systems in the primary glial cell cultures. Annals of the New York Academy of Sciences, 1070, 220–225.
Dufes, C., Alleaume, C., Montoni, A., Olivier, J.-C., et al. (2003). Effects of the vasoactive intestinal peptide (VIP) and relate peptides on glioblastoma cell growth in vitro. Journal of Molecular Neuroscience, 21, 97–108.
Dugan, L. L., Kim, J. S., Zhang, Y., Bart, R. D., et al. (1999). Differential effects of cAMP in neurons and astrocytes. Role of b-Raf. Journal of Biological Chemistry, 274, 25842–25848.
Fabry, M., Cabrele, C., Hocker, H., & Beck-Sickinger, A. G. (2000). Differently labeled peptide ligands for rapid investigation of receptor expression on a new human glioblastoma cell line. Peptides, 21, 1885–1893.
Farini, D., Puglianiello, A., Mammi, C., Siracusa, G., et al. (2003). Dual effect of pituitary adenylate cyclase activating polypeptide on prostate tumor LNCaP cells: Short- and long-term exposure affect proliferation and neuroendocrine differentiation. Endocrinology, 144, 1631–1643.
Ghzili, H., Grumolato, L., Vaudry, H., & Anouar, Y. (2006). Possible implication of the transcriptional regulator Id3 in PACAP-induced pro-survival signaling during PC12 cell differentiation. Regulatory Peptides, 137, 89–94.
Goursaud, S., Pineau, N., Becq-Giraudon, L., Gressens, P., et al. (2005). Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: Implication of a GTP-sensitive form of VPAC1 receptor. Journal of Neuroimmunology, 158, 94–105.
Gozes, I., Fridkin, M., Hill, J. M., & Brenneman, D. E. (1999). Pharmaceutical VIP: Prospects and problems. Current Medicinal Chemistry, 6, 1019–1034.
Harmar, A. J., Arimura, A., Gozes, I., Journot, L., et al. (1998). International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacological Reviews, 50, 265–270.
Heraud, C., Hilairet, S., Muller, J. M., Leterrier, J. F., et al. (2004). Neuritogenesis induced by vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and peptide histidine methionine in SH-SY5y cells is associated with regulated expression of cytoskeleton mRNAs and proteins. Journal of Neuroscience Research, 75, 320–329.
Jaworski, D. M. (2000). Expression of pituitary adenylate cyclase-activating polypeptide (PACAP) and the PACAP-selective receptor in cultured rat astrocytes, human brain tumors, and response to acute intracranial injury. Cell and Tissue Research, 300, 219–230.
Kurino, M., Fukunaga, K., Ushio, Y., & Miyamoto, E. (1996). Cyclic AMP inhibits activation of mitogen-activated protein kinase and cell proliferation in response to growth factors in cultured rat cortical astrocytes. Journal of Neurochemistry, 67, 2246–2255.
Laburthe, M., Couvineau, A., & Tan, V. (2007). Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides, 28, 1631–1639.
Le, S. V., Yamaguchi, D. J., McArdle, C. A., Tachiki, K., et al. (2002). PAC1 and PACAP expression, signaling, and effect on the growth of HCT8, human colonic tumor cells. Regulatory Peptides, 109, 115–125.
Lelievre, V., Meunier, A. C., Caigneaux, E., Falcon, J., et al. (1998a). Differential expression and function of PACAP and VIP receptors in four human colonic adenocarcinoma cell lines. Cellular Signaling, 10, 13–26.
Lelievre, V., Pineau, N., Du, J., Wen, C. H., et al. (1998b). Differential effects of peptide histidine isoleucine (PHI) and related peptides on stimulation and suppression of neuroblastoma cell proliferation. Journal of Biological Chemistry, 273, 19685–19690.
Leyton, J., Coelho, T., Coy, D. H., Jakolew, S., et al. (1998). PACAP(6-38) inhibits the growth of prostate cancer cells. Cancer Letters, 125, 131–139.
Leyton, J., Gozes, Y., Pisegna, J., Coy, D., et al. (1999). PACAP(6-38) is a PACAP receptor antagonist for breast cancer cells. Breast Cancer Research and Treatment, 56, 177–186.
Lu, N., Zhou, R., & DiCicco-Bloom, E. (1998). Opposing mitogenic regulation by PACAP in sympathetic and cerebral cortical precursors correlates with differential expression of PACAP receptor (PAC1-R) isoforms. Journal of Neuroscience Research, 53, 651–662.
Monaghan, T. K., Mackenzie, C. J., Plevin, R., & Lutz, E. M. (2008). PACAP-38 induces neuronal differentiation of human SH-SY5Y neuroblastoma cells via cAMP-mediated activation of ERK and p38 MAP kinase. Journal of Neurochemistry, 104, 74–88.
Moody, T. W., Hill, J. M., & Jensen, R. T. (2003). VIP as a trophic factor in the CNS and cancer cells. Peptides, 24, 163–177.
Nicot, A., & DiCicco-Bloom, E. (2001). Regulation of neuroblast mitosis is determined by PACAP receptor isoform expression. Proceedings of the National Academy of Sciences, 98, 4758–4763.
Nowak, J. Z., & Zawilska, J. B. (2003). PACAP in avians: Origin, occurrence, and receptors—Pharmacological and functional considerations. Current Pharmaceutical Design, 9, 465–481.
Nussdorfer, G. G., & Malendowicz, L. K. (1998). Role of VIP, PACAP, and related peptides in the regulation of the hypothalamo-pituitary–adrenal axis. Peptides, 19, 1443–1467.
Reubi, J. C., Laderach, U., Waser, B., Gebbers, J. O., et al. (2000). Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Research, 60, 3105–3112.
Salomon, Y., Londos, C., & Rodbell, M. (1974). A highly sensitive adenylate cyclase assay. Analytical Biochemistry, 58, 541–544.
Schulz, S., Rocken, C., Mawrin, C., Weise, W., et al. (2004). Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastc human tissues with subtype-specific antibodies. Clinical Cancer Research, 10, 8235–8242.
Sharma, A., Walters, J., Gozes, Y., Fridkin, M., et al. (2001). A vasoactive intestinal peptide antagonist inhibits growth of glioblastoma cells. Journal of Molecular Neuroscience, 17, 331–339.
Shimizu, H., Daly, J. W., & Creveling, C. R. (1969). A radioisotopic method for measuring the formation of adenosine 3′, 5′-cyclic monophosphate in incubated slices of brain. Journal of Neurochemistry, 16, 1609–1619.
Sokolowska, P., & Nowk, J. Z. (2006). Cyclic AMP formation in C6 glioma cells: effect of PACAP and VIP in early and late passages. Annals of the New York Academy of Sciences, 1070, 566–569.
Vallejo, I., & Vallejo, M. (2002). Pituitary adenylate cyclase-activating polypeptide induces astrocyte differentiation of precursor cells from developing cerebral cortex. Molecular and Cellular Neuroscience, 21, 671–683.
Vaudry, D., Gonzalez, B. J., Basille, M., Yon, L., et al. (2000). Pituitary adenylate cyclase-activating polypeptide and its receptors: From structure to functions. Pharmacological Reviews, 52, 269–324.
Vertongen, P., Camby, I., Darro, F., Kiss, R., et al. (1996). VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor. Neuropeptides, 30, 491–496.
Waschek, J. A. (2002). Multiple actions of pituitary adenylyl cyclase activating peptide in nervous system development and regeneration. Developmental Neuroscience, 24, 14–23.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sokolowska, P., Nowak, J.Z. Effects of PACAP and VIP on cAMP-generating System and Proliferation of C6 Glioma Cells. J Mol Neurosci 36, 286–291 (2008). https://doi.org/10.1007/s12031-008-9071-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-008-9071-9